Alimera Sciences, Inc. (ALIM) - Revenue and Sales Volume

Alimera Sciences develops advanced micro-implants for the therapy of retinal pathologies, generating revenue from the sale of the drug Iluvien via insurance payments to ophthalmology centers. The company's sales financial dynamics demonstrate a trend where the value of 0.10 describes the current level. Patent protection allows the brand to maintain high profitability and successfully resist the expansion of affordable generics within its market segment.

ALIM - Alimera Sciences, Inc. Revenue and Sales Volume over the range 07/04/2022 - 09/21/2024

Comprehensive metric breakdowns and analytics for Alimera Sciences Inc (ALIM)

- market value and analyst target forecast:

Market Chart Alimera Sciences|ALIM - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Alimera|ALIM - Total Company Value

- company book value details:

Net Assets per Single Share Alimera Sciences|ALIM - Book Capitalization|Market Capitalization to Book Value alimerasciences.com|ALIM - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

ALIM - Company Net Income|Company Profit Forecast Alimera Sciences|ALIM - P/E Multiple|Projected Price to Earnings Alimera Sciences|ALIM - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Alimera Sciences Inc|ALIM - Operating profit EBITDA|Net earnings per one share for the last twelve months Alimera Sciences|ALIM - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months alimerasciences.com|ALIM - Earnings growth in current year|Expected earnings per share growth for next year Alimera Sciences

- company sales and revenue statistics:

ALIM - Revenue and Sales Volume|Company Expected Sales Volume alimerasciences.com|ALIM - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Alimera Sciences Inc|ALIM - Sales Growth YoY (TTM)

Comprehensive company analysis:Alimera Sciences, Inc. - ALIM

Signature product of Alimera Sciences, Inc.

Ophthalmic implant patents and FDA certification protect Alimera Sciences (ALIM) from competition, ensuring a steady cash flow. Daily revenue dynamics measure real market demand, allowing investors to differentiate short-term fluctuations from a systemic business model crisis by assessing the long-term development vector through the company's aggregate sales volume.

Key competitors